Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy VI: Nursing Management
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Feb 4, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Alexandros Klavdios Steriotis1, Sanjay Sharma1
1CRY Centre for Inherited Cardiovascular Conditions & Sports Cardiology, St George's University of London, London, UK.
Hypertrophic cardiomyopathy (HCM) management focuses on identifying patients at risk of sudden cardiac death (SCD). While implantable cardioverter-defibrillators (ICDs) prevent SCD, refining risk stratification is crucial for optimal patient selection.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: